Premixed vs basal-bolus insulin regimen in Type 2 diabetes: comparison of clinical outcomes from randomized controlled trials and real-world data

Diabetic Medicine

Volumn 34, Issue 12, 2017, Pages 1728-1736

  Anyanwagu, U ^a   Mamza, J ^a   Gordon, J ^a   Donnelly, R ^a   Idris, I ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT;

ARTICLE; CLINICAL OUTCOME; DIABETIC OBESITY; DIABETIC PATIENT; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNITED KINGDOM; WEIGHT CHANGE; WEIGHT REDUCTION; ADULT; AGED; BLOOD; COMPARATIVE STUDY; DOSE CALCULATION; DRUG EFFECT; DRUG FORMULATION; FEMALE; GLUCOSE BLOOD LEVEL; MALE; META ANALYSIS; METABOLISM; MIDDLE AGED; OBSERVATIONAL STUDY; PRIMARY HEALTH CARE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG COMPOUNDING; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; OBSERVATIONAL STUDIES AS TOPIC; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 85031317909     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.13518     Document Type: Article

References (33)

1. DeWitt DE, Hirsch IB. Outpatients insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003; 289: 2254–2264.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993; 329: 977–986.
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10–Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589.
4. Garber AJ. Methods to enhance delivery of prandial insulin and basal-prandial insulin. Diabetes Obes Metab 2013; 15(Suppl 1): 11–17.
5. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193–203.
6. Hamaty M. Insulin treatment for type 2 diabetes: when to start, which to use. Cleve Clin J Med 2011; 78: 332–342.
7. Beluchin E, Bäz L, Müller N, Lehmann T, Kloos C, Wolf G et al. Frequency of self-adjustment of insulin dose and metabolic control in Type 2 diabetes -is there an association? Diabet Med 2013; 30: e91–94.
8. Kramer G, Kuniss N, Kloos C, Lehmann T, Müller N, Sanow B et al. Principles of self-adjustment of insulin dose in people with diabetes type 2 and flexible insulin therapy. Diabetes Res Clin Pract 2016; 116: 165–170.
9. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care 2010; 33: 240–245.
10. Turner HE, Matthews DR. The use of fixed-mixture insulins in clinical practice. Eur J Clin Pharmacol 2000; 56: 19–25.
11. Bowering K, Reed VA, Felicio JS, Landry J, Ji L, Oliveira J. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study. Diabet Med 2012; 29: e263–272.
12. Fritsche A, Larbig M, Owens D, Haring HU. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab 2010; 12: 115–123.
13. Kloos C, Samann A, Lehmann T, Braun A, Heckmann B, Muller UA. Flexible intensive versus conventional insulin therapy in insulin-naive adults with type 2 diabetes: an open-label, randomized, controlled, crossover clinical trial of metabolic control and patient preference. Diabetes Care 2007; 30: 3031–3032.
14. Idris I, Pillai A, Fernando DJ, Thomson G, Tate H. Responders to insulin therapy at 18 months in adults with newly diagnosed diabetes: which insulin regimen? Diabet Med 2013; 30: e95–100.
15. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J Clin Epidemiol 2009; 62: 499–505.
16. Wang C, Mamza J, Idris I. Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabet Med 2015; 32: 585–594.
17. Hirao K, Arai K, Yamauchi M, Takagi H, Kobayashi M. Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11). Diabetes Res Clin Pract 2008; 79: 171–176.
18. Jain SM, Mao X, Escalante-Pulido M, Vorokhobina N, Lopez I, Ilag LL. Prandial–basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes. Diabetes Obesity Metab 2010; 12: 967–975.
19. Levin PA, Zhang Q, Mersey JH et al. Glycemic Control with Insulin Glargine plus Insulin Glulisine versus Premixed Insulin Analogues in Real-World Practices: A Cost-Effectiveness Study With a Randomized Pragmatic Trial Design. Clin Ther 2011; 33: 841–850.
20. Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B et al. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009; 11: 45–52.
21. Miser WF, Arakaki R, Jiang H, Scism-Bacon J, Anderson PW, Fahrbach JL. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a non-inferiority intensification substudy of the DURABLE trial. Clinical Therapeutics 2010; 32: 896–908.
22. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008; 31: 20–25.
23. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011; 19: 251–255.
24. Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med. 2012; 172: 1005–1111.
25. Anyanwagu U, Mamza J, Mehta R, Donnelly R, Idris I. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes. BMJ Heart 2016; 102: 1581–1587.
26. Polonsky WH, Thompson S, Wei W, Riddle MC, Chaudhari S, Jackson J, Bruno AS. Greater fear of hypoglycaemia with premixed insulin than with basal-bolus insulin glargine and glulisine: patient-reported outcomes from a 60-week randomised study. Diabetes Obes Metab 2014; 16: 1121–1127.
27. Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 2011; 13: 1008–1019.
28. Concert CM, Burke RE, Eusebio AM, Slavin EA, Shortridge-Baggett LM. The Effectiveness of Motivational Interviewing on Glycemic Control for Adults with Type 2 Diabetes Mellitus (DM2): A Systematic Review. JBI Libr Syst Rev. 2012; 10(42 Suppl): 1–17.
29. Paul SK, Shaw J, Montvida O, Klein K. Weight gain in insulin treated patients by BMI categories at treatment initiation: New evidence from real-world data in patients with type 2 diabetes. Diabetes Obes Metab 2016; 18: 1244–1252.
30. Balkau B, Home PD, Vincent M, Marre M, Freemantle N. Factors associated with weight gain in people with type 2 diabetes starting on insulin. Diabetes Care 2014; 37: 2108–2113.
31. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736–1744.
32. Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006: CD003287.
33. Müller N, Lehmann T, Gerste B, Adler JB, Kloos C, Hartmann M et al. Increase in the incidence of severe hypoglycaemia in people with Type 2 diabetes in spite of new drugs: analysis based on health vvinsurance data from Germany. Diabet Med 2017; 34: 1212–1218.